FINWIRES · TerminalLIVE
FINWIRES

Everpure's Raised Fiscal 2027 Guidance Is 'Still Very Beatable,' Wedbush Says

By

Everpure's (P) updated fiscal 2027 guidance is reasonable, although "still very beatable," as the system average selling price continued to rise through Q2 and ended with system pricing up by triple digits, Wedbush said in a Thursday note.

While pricing is expected to continue benefiting results through the second half of fiscal 2027, Wedbush said revenue from a second top-five hyperscale customer is expected to be de minimis in fiscal 2027, with a meaningful ramp beginning in fiscal 2028.

Strong second-half revenue from Meta, however, should aid comparisons.

Everpure now expects fiscal 2027 revenue of $5.03 billion to $5.07 billion, compared with its previous guidance of $4.41 billion to $4.51 billion.

Meanwhile, fiscal 2027 non-GAAP operating profit is now expected to be $940 million to $960 million, up from $820 million to $860 million previously.

Wedbush raised its price target to $130 from $127 and maintained its outperform rating.

Price: $96.12, Change: $-12.78, Percent Change: -11.74%

Related Articles

Wire

Update: Magellan Financial Group Fiscal 2026 Operating Earnings, Revenue Down; Shares Fall 12%

(Updates to add stock movement in the headline and the last paragraph)Magellan Financial Group (ASX:MFG) logged AU$0.828 in operating earnings per share for fiscal 2026, compared with AU$0.898 a year ago, a Thursday filing showed.For the 12 months ended June 30, revenue and other income was AU$195.6 million versus AU$318.9 million previously, the Australia-listed financial services firm added.The board declared a final dividend of AU$0.255 per share, payable Sept. 16 to shareholders on record as of Sept. 2. A year ago, the company paid a final dividend AU$0.259 per share and special dividend of AU$0.21 per share.The board has revised the group's dividend policy from fiscal 2027, targeting a payout ratio of 60% to 90% of operating profit after tax.The company's shares fell 12% in recent Thursday trade.

ASX:MFG
Wire

Tenable to Join S&P SmallCap 600 Index

Tenable (TENB) will join the S&P SmallCap 600 index before market open on Aug. 31, the S&P Dow Jones Indices said in a late Wednesday statement.Tenable will replace Leggett & Platt (LEG), which is being acquired by Somnigroup International (SGI), according to the statement.

$LEG$SGI$TENB
Wire

NeoGenomics Wins Expanded Medicare Coverage for RaDaR ST Immunotherapy Monitoring

NeoGenomics (NEO) said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.The determination from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program is the third Medicare-covered indication for RaDaR ST, NeoGenomics said Wednesday in a statement.The coverage allows use of the assay to monitor response to immune-checkpoint inhibitor therapy, and NeoGenomics said it has two additional RaDaR ST submissions pending.NeoGenomics shares rose 2.1% in after-hours trading.

$NEO